Weekly paclitaxel in metastatic breast cancer patients: A phase II study

Tumori

Volumn 88, Issue 6, 2002, Pages 470-473

  Gori, Stefania ^a   Mosconi, Anna Maria ^a   Basurto, Carlo ^a   Cherubini, Roberta ^a   De Angelis, Verena ^b   Tonato, Maurizio ^a   Colozza, Mariantonietta ^a  

^a Policlinico Hospital   (Italy)

^b ASL 2   (Italy)

Author keywords

Metastatic breast cancer; Weekly paclitaxel therapy

Indexed keywords

ANTHRACYCLINE; PACLITAXEL;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; BREAST CANCER; CANCER GROWTH; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONTINUOUS INFUSION; DIARRHEA; DISEASE COURSE; DOSE TIME EFFECT RELATION; DRUG ACTIVITY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; HYPERSENSITIVITY REACTION; LEUKOPENIA; MAJOR CLINICAL STUDY; METASTASIS; MYALGIA; NAUSEA; NEUROPATHY; ONYCHOLYSIS; PHASE 2 CLINICAL TRIAL; SENSORY DYSFUNCTION; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

EID: 0036880264     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160208800607     Document Type: Article

References (18)

1. Greenberg PAC, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU: Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol, 14: 2197-2205, 1996.
2. Crump M, Gluck S, Steward D, Levine M, Pritchard K, Kirbride P, Dancey J, O'Reilly S, Shore T, Couban S, Girouard C, Abu-Zahra H, Tu D, Marlin S, Shepherd L: A randomized trial of high-dose chemotherapy (HDC) with autologous peripheral blood stem cell support (ASCT) compared to standard therapy in women with metastatic breast cancer: a National Cancer Institute of Canada (NClC) Clinical Trials Group Study. Proc ASCO, 20: 82A, 2001.
3. Lotz JP, Curé H, Janvier M, Morvan F, Asselain B, Guillemot M, Laadem A, Maraninchi D, Gisselbrecht C, Roché H and the PEGASE Group: High-dose chemotherapy with hematopoietic stem cells transplantation for metastatic breast cancer: results of the French protocol Pegase 04. Proc ASCO, 18: 161A, 1999.
4. Peters W, Joens R, Vredenburg J, Shpall EJ, Hussein A, Elkordy M, Rubin P, Ross M, Berry D: A large prospective randomized trial of high-dose combination alkylating agents (CPB) with autologous cellular support as a consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction therapy (AFM). Proc ASCO, 15: 149A, 1996.
5. Gianni L: High-dose chemotherapy for breast cancer: any use for it? Ann Oncol, 13: 650-652, 2002.
6. Seidman AD, Hudis CA, Albanel J, Tong W, Tepler I, Currie V, Moynahan ME, Theodoulou M, Gallub M, Baselga J, Norton L: Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol, 16: 3353-3361, 1998.
7. Breier S, Lebedinsky C, Ayiviri C, Roffé C, Traine G, Cot C, Politi P: Long-term weekly paclitaxel in metastatic breast cancer (MBC). A phase II trial in pretreated patients. Proc ASCO, 17: 740A, 1998.
8. Norton L: Evolving concepts in the systemic drug therapy of breast cancer. Semin Oncol, 24 (suppl 10): 10.3-10.0, 1997.
9. Beloti D, Vergani V, Drudis T, Borsotti P, Pitelli MR, Viale G, Giavazzi R, Taraboletti G: The microtubule-affecting drug paclitaxel has angiogenic activity. Clin Cancer Res, 2: 1843-1849, 1996.
10. Milross CG, Mason KA, Hunter NR, Chung W-K, Peters LJ, Milas L: Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J Natl Cancer Inst, 88: 1308-1314, 1996.
11. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer, 47: 207-214, 1981.
12. Kaplan EL, Meier P: Non parametric estimation from incomplete observations. J Am Statist Assoc, 53: 457-481, 1958.
13. Perez EA, Vogel CL, Irwin DH, Kirshner JJ, Patel R: Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol, 19: 4216-4223, 2001.
14. Tokuda Y, Asaga T, Yoshida A, Shimizu S, Fujisawa J, Tachibana A, Katayama K, Kubota M, Inaba M, Fukuma E, Fukuda M, Ishida K, Ishiyama A, Suda T: A multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer: Kanagawa Breast Cancer Treatment Society (KBCTS00-02). Proc ASCO, 21: 2021A, 2002.
15. Sola C, Lluch A, Garcia-Conde J, Salazar R, Garcia T, Montesinos J, Vera R, Benavides M, Climent MA, Homedo J, Alvarez I, Prosper F, Cotes-Funes H, Lopez JJL, SOLTI Group: Phase II study of weekly paclitaxel treatment in recurrent breast cancer after high-dose chemotherapy. Proc ASCO, 18: 245A, 1999.
16. Mickiewicz E, Alvarez AM, Brosio C, Giglio R, Cinat G, Rodger J, Nicolas J: A promising second line treatment with weekly taxol in anthracycline recurrent, advanced breast cancer patients. Proc ASCO, 18: 515A, 1999.
17. Alvarez AM, Mickiewicz E, Brosio C, Giglio R, Cinat G, Rodger J, Nicolas C: Reinduction of response with weekly taxol in advanced breast cancer. Proc ASCO, 18: 636A, 1999.
18. Waintraub SE, Cantwell S, DeVries J: Phase II study to evaluate the efficacy of weekly paclitaxel in patients with metastatic breast cancer who have failed prior anthracycline +/- taxane therapy. Proc ASCO, 19: 470A, 2000.